There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738
Recruiting
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be give... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Clinical Trial Site, Houston, Texas
Conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Register for Updates
A Phase 2b Study of Zagociguat in Patients With MELAS
NCT06402123
Recruiting
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Register for Updates
Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
NCT06420206
Recruiting
To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer, Gastrointestinal Cancer
Register for Updates
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
NCT06507878
Recruiting
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Thyroid Cancer
Register for Updates
ACT-Together (Acting on Cancer Testing-Together)
NCT06549153
Recruiting
To determine the feasibility of a group-based education intervention to improve adherence to recommend surveillance and risk reducing procedures, with a focus at medically underserved women and racial/ethnic minorities with BRCA 1 and 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer
Register for Updates
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
NCT06567314
Recruiting
To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cutaneous Squamous Cell Carcinoma
Register for Updates
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
NCT06576037
Recruiting
An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: DM Clinical Research - CyFair Clinical Research Center, Houston, Texas
Conditions: SARS-CoV2, COVID-19
Register for Updates
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
NCT06736600
Recruiting
A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Peripheral Neuropathy Due to Chemotherapy
Register for Updates
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: NEXT Houston, Houston, Texas
Conditions: Solid Tumors
Register for Updates
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
NCT05834244
Recruiting
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: M.D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Clinical Research Solution: Endocrine and Psychiatry Center, 9539 Huffmeister Rd,, Houston, Texas
Conditions: Post-Bariatric Hypoglycemia
Register for Updates